Genomic Vision SA
PAR:GV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Genomic Vision SA
Current Portion of Long-Term Debt
Genomic Vision SA
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Genomic Vision SA
PAR:GV
|
Current Portion of Long-Term Debt
€197k
|
CAGR 3-Years
-12%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
|
Valneva SE
PAR:VLA
|
Current Portion of Long-Term Debt
€20.6m
|
CAGR 3-Years
-18%
|
CAGR 5-Years
16%
|
CAGR 10-Years
-2%
|
|
|
G
|
Genfit SA
PAR:GNFT
|
Current Portion of Long-Term Debt
€2m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
|
Inventiva SA
PAR:IVA
|
Current Portion of Long-Term Debt
€31.9m
|
CAGR 3-Years
76%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
DBV Technologies SA
PAR:DBV
|
Current Portion of Long-Term Debt
$1.1m
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Abivax SA
PAR:ABVX
|
Current Portion of Long-Term Debt
€1.3m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Genomic Vision SA
Glance View
Génomic Vision SA is a molecular diagnostics and technology company, which develops and commercializes research tools and tests for the early detection of cancers and genetic diseases. The company is headquartered in Bagneux, Ile-De-France. The company went IPO on 2014-04-02. The company develops and commercializes single-DNA molecule diagnostic tests and research tools for life sciences, cancer and genetic diseases. The firm uses the molecular combining technique for the direct visualization of single DNA molecules to detect quantitative and qualitative changes in the genome landscape and establish their contribution to pathology. The company develops its products and services in three main markets: the medical diagnostic market focusing on DNA diagnostics (cancer genomics, genetic diseases); the pharmaceutical research and development market in the fields of genomics, to develop tests that can help physicians identify how patients are likely to respond to targeted therapies (personalized medicine, pharmacogenomics, cancer cell proliferation); and the academic laboratories research market, providing molecular combining tools for academic research in the field of cancer genetics, cytogenetics and DNA replication.
See Also
What is Genomic Vision SA's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
197k
EUR
Based on the financial report for Jun 30, 2023, Genomic Vision SA's Current Portion of Long-Term Debt amounts to 197k EUR.
What is Genomic Vision SA's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 5Y
3%
Over the last year, the Current Portion of Long-Term Debt growth was -29%. The average annual Current Portion of Long-Term Debt growth rates for Genomic Vision SA have been -12% over the past three years , 3% over the past five years .
